- ISIN
- US4923271013
- CUSIP
- 492327101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 8, 2020
Highlights
- EPS (TTM)
- -$2.86
- Total Revenue (TTM)
- $33.18M
- Gross Profit (TTM)
- $31.65M
- EBITDA (TTM)
- -$95.52M
- Year Range
- $9.69 - $22.55
- Target Price
- $102.60
- ROA (TTM)
- -27.26%
- ROE (TTM)
- -29.81%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KROS Performance Chart
Keros Therapeutics, Inc. (KROS) is down 46.1% since the beginning of the year. At $11 per share, KROS is trading 51.3% below its 52-week high of $23. Investors who bought $1,000 worth of KROS shares 5 years ago would now be looking at an investment worth $246.
Loading charts...
Returns By Period
Keros Therapeutics, Inc. (KROS) has returned -46.07% so far this year and -18.61% over the past 12 months.
Keros Therapeutics, Inc.
- 1D
- 3.10%
- 1M
- -1.88%
- YTD
- -46.07%
- 6M
- -48.55%
- 1Y
- -18.61%
- 3Y*
- -35.79%
- 5Y*
- -24.44%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
KROS Monthly Returns History
Based on dividend-adjusted daily data since Apr 8, 2020, KROS's average daily return is +0.07%, while the average monthly return is +1.65%. At this rate, an investment would double in approximately 3.5 years.
Historically, 45% of months were positive and 55% were negative. The best month was Aug 2020 with a return of +66.8%, while the worst month was Dec 2024 at -72.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.
On a daily basis, KROS closed higher 49% of trading days. The best single day was Sep 27, 2021 with a return of +32.5%, while the worst single day was Dec 12, 2024 at -73.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.03% | -20.77% | -22.20% | 0.72% | 1.17% | -2.40% | -46.07% | ||||||
| 2025 | -27.98% | -2.81% | -8.03% | 41.71% | -2.01% | -5.65% | 7.27% | 6.22% | 4.01% | -3.79% | 14.85% | 16.48% | 28.62% |
| 2024 | 39.24% | 21.93% | -1.93% | -14.82% | -16.88% | -2.50% | 9.76% | -9.59% | 28.05% | -0.05% | -0.52% | -72.58% | -60.19% |
| 2023 | 21.97% | -9.13% | -19.77% | 3.88% | 7.90% | -16.05% | 4.23% | -16.17% | -9.20% | -10.48% | 6.31% | 31.05% | -17.20% |
| 2022 | -20.75% | 15.81% | 1.27% | -2.52% | -36.24% | -18.25% | 16.11% | 10.26% | 6.36% | 33.81% | -0.99% | -3.65% | -17.93% |
| 2021 | -19.12% | 14.76% | -5.99% | -4.47% | -7.21% | -22.16% | -13.35% | -8.59% | 17.60% | 5.46% | 33.72% | 4.88% | -17.05% |
Benchmark Metrics
Keros Therapeutics, Inc. has an annualized alpha of -1.58%, beta of 1.11, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since April 08, 2020.
- This stock participated in 167.25% of S&P 500 Index downside but only 61.08% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -1.58%
- Beta
- 1.11
- R²
- 0.08
- Upside Capture
- 61.08%
- Downside Capture
- 167.25%
Return for Risk
Risk / Return Rank
KROS ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Keros Therapeutics, Inc. (KROS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KROS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.42 | ||
| Sortino ratioReturn per unit of downside risk | -3.03 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.37 | -0.40 |
| Calmar ratioReturn relative to maximum drawdown | -0.34 | 2.78 | -3.13 |
| Martin ratioReturn relative to average drawdown | -0.66 | 12.44 | -13.10 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Keros Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Keros Therapeutics, Inc. was 88.46%, occurring on Apr 1, 2025. The portfolio has not yet recovered.
The current Keros Therapeutics, Inc. drawdown is 86.73%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -88.46%Apr 2025 | 4y 3mo | — | 5y 6moDec 2020 - now |
2020 bear market2020 | -42.13%Oct 2020 | 1mo 11d | 22d | 2mo 3dAug 2020 - Oct 2020 |
2020 bear market2020 | -33.05%Jul 2020 | 28d | 25d | 1mo 23dJun 2020 - Aug 2020 |
2020 correction2020 | -18.05%Nov 2020 | 4d | 14d | 18dOct 2020 - Nov 2020 |
2020 correction2020 | -13.40%May 2020 | 27d | 7d | 1mo 4dApr 2020 - Jun 2020 |
Drawdown Indicators
| KROS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.46% | -56.78% | -31.68% |
Max Drawdown (1Y)Largest decline over 1 year | -54.62% | -9.10% | -45.52% |
Max Drawdown (3Y)Largest decline over 3 years | -86.45% | -18.90% | -67.55% |
Max Drawdown (5Y)Largest decline over 5 years | -86.45% | -25.43% | -61.02% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -86.73% | -1.80% | -84.93% |
Average DrawdownAverage peak-to-trough decline | -48.64% | -10.71% | -37.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.28% | 2.03% | +26.25% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Keros Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Keros Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KROS relative to other companies in the Biotechnology industry. Currently, KROS has a P/S ratio of 9.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KROS
Add Keros Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KROS